Table 1.
Biologic pathways | Biochemical markers | Specimen type | Gestational age at specimen collection* | Definition of spontaneous preterm birth | |||||
---|---|---|---|---|---|---|---|---|---|
Early pregnancy (<14 weeks of gestation) | Mid pregnancy (14–28 weeks of gestation) | Late pregnancy (>28 weeks of gestation) | <32 weeks | <34 weeks | <35 weeks | <37 weeks | |||
Intrauterine infection and inflammation | |||||||||
Bacterial vaginosis | [5, 25] | [25] | [25] | [25] | [5] | [25] | |||
Interleukin (IL)-6 | Cervical | [27, 29] | [27] | [28, 29] | |||||
Serum | [29–31] | [31] | [30] | [31] | [28, 29] | ||||
C-reactive protein | Serum | [30, 32–34] | [30, 33] | [28, 32–34] | |||||
IL-1, IL-2, IL-8, and tumor necrosis factor-α | Cervical | [29, 34] | [29, 34] | ||||||
Serum | [29–31] | [30] | [31] | [29] | |||||
Extracellular matrix degradation | |||||||||
Fetal fibronectin | Cervicovaginal | [31, 35, 36, 38, 39, 42, 43] | [43] | [42, 44] | [31, 35, 36, 38, 39] | [43] | |||
Fetal stress | |||||||||
Corticotropin-releasing hormone | Serum | [31, 46, 47] | [46] | [31, 47] | [46] | ||||
Fetal anomalies | |||||||||
α-Fetoprotein | Serum | [20, 22, 31, 47] | [20, 22, 31, 47] | ||||||
β-Human chorionic gonadotropin | Cervicovaginal | [49] | [48] | [49] | [48] | ||||
Estrogen metabolism | |||||||||
Estriol | Salivary | [53, 54] | [53, 54] | [54] | [54] | [54] | [53, 54] |
*Gestational age at specimen collection available for individual studies and not for meta-analysis or systematic reviews due to variations in timing of specimen collection for studies included in authors' pooled analysis.